# TheraP (NCT03392428)

> A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03392428
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Conditions: Cancer of the Prostate; Metastatic Cancer
- Interventions: 177Lu-PSMA617; Cabazitaxel
- Enrollment: 201
- Primary outcome: Prostate Specific Antigen response rate (PSA RR)

## Commentary we found

- X threads: 84
- YouTube: 13
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=therap-nct03392428

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03392428", "email": "<work email>"}; the inbox owner confirms by the emailed link.